FDL has a robust pipeline of CFTR “correctors,” “potentiators,” and “2nd generation modulators” as well as backup compounds for each of these approaches. FDL169 has been in multiple Phase I clinical trials in both healthy volunteers and patients with CF. FDL176 is also in clinical development. We continue to optimize our “second generation correctors”.
- FDL169: F508del-CFTR Corrector 80%
- FDL169 Back-up 38%
- FDL176: CFTR Potentiator 70%
- FDL176 Back-up 30%
- Second Generation Modulators 50%